<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451098</url>
  </required_header>
  <id_info>
    <org_study_id>152PDL14025</org_study_id>
    <nct_id>NCT02451098</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-391</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Factorial Design, Phase III Clinical Trial To Evaluate the Efficacy and Safety of Atorvastatin+Ezetimibe Combination Therapy and Atorvastatin Monotherapy in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Factorial Design,
      Phase III Clinical Trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this phase 3 study was to evaluate the efficacy and safety of CKD-391 once daily
      for 8 weeks in patients with primary hypercholesterolemia. Furthermore, the extension study
      for additional 12 weeks is designed to confirm long term safety of CKD-391.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change form baseline in LDL-C</measure>
    <time_frame>up to week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in LDL-C</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Total cholesterol</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Triglyceride</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in HDL-C</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Non-HDL-C</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in LDL-C/HDL-C ratio</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in TC/HDL-C ratio</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Non-HDL-C/HDL-C ratio</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Apo-B ratio</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Apo-B</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Apo-A1</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in Apo-B/Apo-A1 ratio</measure>
    <time_frame>up to week 20</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate safety of CKD-391 from adverse events, laboratory test results, physical examination, vital signs.</measure>
    <time_frame>up to week 20</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin10mg, Ezetimibe10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin10mg, Ezetimibe placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin10mg, placebo will be administered (Duration 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin20mg, Ezetimibe10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin20mg, Ezetimibe placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin20mg, placebo will be administered (Duration 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin40mg, Ezetimibe10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin40mg, Ezetimibe placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin40mg, placebo will be administered (Duration 8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin10mg, Ezetimibe10mg</intervention_name>
    <description>Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)</description>
    <arm_group_label>Atorvastatin10mg, Ezetimibe10mg</arm_group_label>
    <other_name>CKD-391</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin10mg, Ezetimibe placebo</intervention_name>
    <description>Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)</description>
    <arm_group_label>Atorvastatin10mg, Ezetimibe placebo</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin20mg, Ezetimibe10mg</intervention_name>
    <description>Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)</description>
    <arm_group_label>Atorvastatin20mg, Ezetimibe10mg</arm_group_label>
    <other_name>CKD-391</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin20mg, Ezetimibe placebo</intervention_name>
    <description>Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)</description>
    <arm_group_label>Atorvastatin20mg, Ezetimibe placebo</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin40mg, Ezetimibe10mg</intervention_name>
    <description>Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)</description>
    <arm_group_label>Atorvastatin40mg, Ezetimibe10mg</arm_group_label>
    <other_name>CKD-391</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin40mg, Ezetimibe placebo</intervention_name>
    <description>Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)</description>
    <arm_group_label>Atorvastatin40mg, Ezetimibe placebo</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, at least 19 years of age.

          -  Hyperlipidemia patient of LDL-C≤250 mg/dl and TG ≤400 mg/dl

          -  Patients requiring anti-dyslipidemia drug therapy [based on the NCEP ATP III(2002)]

          -  Drug compliance during Run-in period ≥70%

          -  Patients must willing to the study and signed an informed consent

        Exclusion Criteria:

          -  Patients with myopathy included rhabdomyolysis or CPK level≥2xULN

          -  Patients with acute arterial disease

          -  Patients with renal dysfunction or Serum creatinine level ≥2x ULN

          -  Patients with liver dysfunction or ALT, AST level &gt; 2xULN

          -  Patients with medical history within 6 months prior to screening visit (Heart failure,
             uncontrolled arrhythmia, drug and alcohol abuse history, gastrointestinal disease or
             surgery, anticoagulation disease)

          -  Patient with uncontrolled disease (diabetes mellitus as HbA1c level of &gt; 9.0%,
             hypertension as SBP≥180mmHg or DBP≥110mmHg, hypothyroidism as TSH≥1.5xULN)

          -  Patients who have a history or presence of active malignancy within 5 years

          -  Patients with difficulty of stop taking lipid-lowering agents during run-in period.

          -  Patients who have taken another investigational drug within 4 weeks prior to screening
             visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho-Jung Yoon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The catholic university of korea seoul st. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

